Skip to main content
Premium Trial:

Request an Annual Quote

Anagnostics Taps Peak-Service to Offer Field Support in Europe, US


By Justin Petrone

Austrian microarray firm Anagnostics Bioanalysis has inked a deal with Darmstadt, Germany-based Peak-Service to offer field support for customers in Europe and the US, Anagnostics said last week.

Anagnostics last month began shipping its Hyborg microarray platform, which uses the firm's cylindrical Hybcell microarrays, to early-access customers in Austria and Germany. The deal with Peak-Service is designed to help Anagnostics support its first customers in these regions as it ramps up for full commercial launch by the end the year, according to the company's CEO.

Christoph Reschreiter told BioArray News in an e-mail this week that St. Valentin-based Anagnostics had been providing field support for its products before it signed the deal with Peak-Service last month. The company is now training Peak-Service technicians and expects them to be ready to provide field support by the end of this month.

Anagnostics, founded in 2005, employs 10 staffers who are currently focused on R&D and sales, Reschreiter said. The company is now free to "concentrate our efforts on research and development as well as sales" while the outsourcing of field support gives the firm's customers "immediate access to an Europe-wide network of experienced experts in diagnostics and research devices," he said.

More than 100 enginners work for Peak-Service, according to a statement. The company claims to provide services in Europe and the US.

Financial terms of the deal were not discussed.
While traditional microarrays are printed on slides, Anagnostic's Hybcell arrays are composed of detector molecules, DNA or proteins, which are immobilized on the surface of an inner cylinder. This cylinder is enclosed within a cylindrical container. Users fill this external cylinder with their sample, and up to 96 Hybcell arrays can be processed at a time in the company's Hyborg system, which integrates a thermal cycler, a hybridization station, and a scanner, according to the company.

Since the cylindrical arrays are rotated within the Hyborg, Anagnostics claims that its approach offers faster hybridization and binding than other approaches. "Because of the movement of the sample against the array and the agitation, you have much more stable assay conditions," Reschreiter told BioArray News last month. "It's like stirring when you are cooking" (see BAN 2/9/2010).

Current Hybcell arrays are designed to allow users to survey up to 200 different biomarkers per array, though Reschreiter said at the time the company has enough real estate on its Hybcells to potentially look at 2,000 markers. Reschreiter said that the Hybcell's cylindrical nature allows the firm to provide kinetic measurements.

Anagnostics' two methods in development are for affinity measurement and on-spot reactions. In terms of on-spot reactions, Anagnostics is trying to integrate PCR and hybridization in a single step on its arrays. "That way we can combine cycling and hybridization and measurement," Reschreiter said at the time. "This is what we want to use for on-spot PCR."

Anagnostics is also developing a number of themed Hybcell arrays with a long-term view towards molecular diagnostics. Reschreiter said the company has programs in drugs of abuse, infectious disease testing, and oncology. The company has provided no timeline for when it hopes to have diagnostic assays on the market.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more